Zefti shows 99.2% inhibition of Type A flu virus in long-term organoids

Hyun Dae Bio Science announced that its candidate antiviral drug, 'Zefti,' has demonstrated a 99.2% inhibition rate against the H1N1 influenza A virus in human lung organoids. The active ingredient, niclosamide, was tested using organoids derived from human embryonic stem cells differentiated into lung alveolar cells.

The study, part of the Ministry of Science and ICT's 'National Preclinical Support System Project,' was carried out at the National Preclinical Trial Center (KPEC) of the Korea Research Institute of Bioscience and Biotechnology. After infecting the organoids with H1N1, the relative expression of HA mRNA was measured four times at different concentrations on the third day of infection. The results showed a significant viral suppression effect, with the niclosamide-treated group showing an average of 101.692 compared to the untreated control group's 12,858.439.

“

The trend of educational grants has been around 6% for the past 20 years. We will guarantee that trend. The remaining money will be used for higher education, lifelong learning, and early childhood education.

No harmful effects such as in vivo accumulation or genotoxicity were observed. The company is currently researching the compound's efficacy against various viruses and diseases simultaneously. The principle behind this broad-spectrum approach is that niclosamide targets host cell pathways common to different viruses, suggesting it could be effective regardless of variations in viral genetic structures or intracellular replication methods.

“

A universal antiviral drug cannot be realized by developing a new one for every virus mutation. The same effective drug concentration must be consistently confirmed under different conditions, such as cells, animals, and human tissues. This result confirms that consistency.

Previously, Zefti's efficacy against the COVID-19 virus was confirmed in a Phase 2 clinical trial. The company is also conducting Phase 2/3 trials for dengue fever in Vietnam. In the United States, discussions are underway with Professor David Davis Smith, an immunology expert at the University of California, San Diego, for a 'proactive treatment basket clinical study' to assess the therapeutic effects of simultaneous administration against influenza, COVID-19, and RSV (Respiratory Syncytial Virus).

Jin Geun-woo, CEO of Hyun Dae Bio, stated, "A universal antiviral drug cannot be realized by developing a new one for every virus mutation. The same effective drug concentration must be consistently confirmed under different conditions, such as cells, animals, and human tissues. This result confirms that consistency." Bae Byung-joon, President of Hyun Dae Bio, added, "After receiving Professor Smith's proposal, we decided to proceed with clinical trials only after confirming the possibility of success. This organoid test is part of the process to confirm the safety and genotoxicity in the Vietnamese dengue fever clinical trial."

“

After receiving Professor Smith's proposal, we decided to proceed with clinical trials only after confirming the possibility of success. This organoid test is part of the process to confirm the safety and genotoxicity in the Vietnamese dengue fever clinical trial.